European review for medical and pharmacological sciences
-
Eur Rev Med Pharmacol Sci · Feb 2021
SARS-CoV-2 and finding of vein thrombosis: can IMPROVE and IMPROVEDD scores predict COVID-19 outcomes?
Diffuse thrombosis represents one of the most predominant causes of death by COVID-19 and SARS-CoV-2 infection seems to increase the risk of developing venous thromboembolic diseases (VTE). Aim of this study is to analyze the relationship between validated predictive scores for VTE such as IMPROVE and IMPROVEDD and: (1) Intensification of Care (IoC, admission to Pulmonology Department or Intensive Care Unit) (2) in-hospital mortality rate 3) 30-days mortality rate. ⋯ IMPROVE score can be considered an independent predictor of in-hospital and 30-days mortality.
-
Eur Rev Med Pharmacol Sci · Feb 2021
Observational StudyHigh levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
This study evaluated the ability of mid-regional proadrenomedullin (MR-proADM) to identify disease severity in Coronavirus disease 2019 (COVID-19) patients in comparison to conventional inflammatory biomarkers and clinical scores. ⋯ MR-proADM, in addition to the clinical scores, could be useful to predict outcome in COVID-19 ARDS patients.
-
Eur Rev Med Pharmacol Sci · Jan 2021
Meta AnalysisEffects of non-drug interventions on depression, anxiety and sleep in COVID-19 patients: a systematic review and meta-analysis.
Patients with Coronavirus Disease 2019 (COVID-19) suffer from anxiety, depression and sleep disorders due to isolation treatment, among other reasons. Whether non-drug interventions can be alternative therapies for COVID-19 patients with anxiety, depression and sleep disorders is controversial. Therefore, we conducted a meta-analysis and systematic review to evaluate the effects of non-drug interventions on anxiety, depression and sleep in patients with COVID-19 to provide guidance for clinical application. ⋯ This meta-analysis found that non-drug interventions can reduce the anxiety and depression scores of patients with COVID-19. Due to the limitations of this study, more high-quality studies are needed to verify the findings, especially the effect of non-drug interventions on improving the sleep status of COVID-19 patients.
-
Eur Rev Med Pharmacol Sci · Jan 2021
Observational StudyHealthcare workers' knowledge and attitudes towards COVID-19 in Saudi Arabia.
The world is facing a devastating challenge in the COVID-19 (coronavirus disease 19) outbreak. Healthcare workers (HCWs) provide the first line of defense against any disease outbreak. Thus, the present study is designed to assess HCWs' attitudes towards, knowledge of, and awareness of COVID-19. ⋯ The findings of this work can support the design of effective measures to prevent and control COVID-19 infections during the pandemic. The results also highlight where improvement is needed to HCWs' knowledge of and attitudes towards COVID-19; the findings also highlight the best healthcare practices regarding this illness.
-
Eur Rev Med Pharmacol Sci · Jan 2021
ReviewPrescribing cascades and medications most frequently involved in pain therapy: a review.
The aging of the population and chronic pain represents topical issues in developed countries. These often translate into polypharmacy, inappropriate medications, and adverse drug events, with the risk of misinterpreting these latter with new medical conditions, generating what is referred to prescribing cascade. Prescribing cascades may lead to the prescription of new drugs, which could cause new potential side effects and unnecessary costs for individuals and healthcare systems. Therefore, the purpose of our review was to collect a good deal of prescribing cascades examples involving pain therapy medicines, to help clinicians minimize drug-related clinical outcomes. ⋯ This study provides a list of several examples of prescribing cascades in pain medicine and is essential to raise awareness of the potential dangers they could involve in all patient populations. Collaboration between clinicians and clinical pharmacologists may lead to more appropriate polypharmacy schemes.